Take a look at Acclinate’s CEO Del Smith, PhD and Chief Medical Lead Camille Pope, PharmD's discussion on increasing recruitment and retention of communities of color in clinical trials.Check it out!
NOWINCLUDED has been selected as an honorable mention by Fast Company's World Changing Ideas Awards for the second year in a row.Check it out!
Acclinate uses sustained community engagement and technology to achieve more inclusive clinical research.Learn more
Read our take on the U.S. Food and Drug Administration's important step to increase racial and ethnic diversity in clinical trials.
We help pharmaceutical companies and healthcare organizations access and engage communities of color so research is more inclusive.
Pre-engagement and awareness is necessary to build trust with communities of color who may be skeptical of participating in clinical research.
Acclinate increases trust and awareness of research-related health topics in communities of color through our NOWINCLUDED platform.
With our team of culturally-competent community engagement specialists, Acclinate engages most likely participants of specific research-related health issues (e.g., health disparities, common misdiagnoses, sources of information, options for care).
Acclinate's predictive analytics tool, e-DICT, helps pharmaceutical companies and health organizations present their trial to likely participants, driving down recruitment costs and increasing diverse enrollment.
Month-over-month community growth
Total participants sought for current client studies
Average diversity target for current client studies
Acclinate's predictive analytics software, e-DICT, helps pharmaceutical companies and health organizations identify and hyper-target likely participants for their clinical research, driving down recruitment costs and increasing diverse enrollment.Contact us here →
"Trust is driven by relationships. The key to diversity is inclusion, we strive to include minorities in conversations, not as a statistic, as a human being."
“We partnered with Acclinate because their platform and services will lead to successful recruitment and engagement of study participants for our first of its kind, ARGONAUT study.”
Stephanie Culler, Ph.D.
Persephone Biosciences, Inc.
“Acclinate is at the forefront of implementing a portal to make certain minorities are included in clinical trials.”
Randall Moreadith, MD, PhD